Percutaneous transluminal coronary angioplasty, alone or in combination with urokinase therapy, during acute myocardial infarction

Jpn Circ J. 1999 Feb;63(2):91-6. doi: 10.1253/jcj.63.91.

Abstract

To investigate the effect of pre-treatment of a thrombus with a low dose of urokinase on establishing patency in a persistent infarct-related artery (IRA) during direct percutaneous coronary angioplasty (PTCA), the frequency of acute restenosis during direct PTCA, alone, or in combination with the intracoronary administration of urokinase, was examined in a consecutive nonrandomized series of patients with acute myocardial infarction (AMI). Two hundred and seventy-two successful PTCA patients (residual stenosis <50%) were divided into 2 groups: 88 patients received pre-treatment with intracoronary urokinase following PTCA (combination group); 184 received only direct PTCA without thrombolytic therapy (PTCA group). In the present study, after achievement of a residual stenosis of less than 50%, IRA was visualized every 15 min to assess the frequency of acute restenosis, which was defined as an acute progression of IRA with more than 75% restenosis after initially successful PTCA. In the patients with a large coronary thrombus, the frequency (times) of acute restenosis was significantly lower in the combination group than in the PTCA group (0.98+/-0.19 vs 2.92+/-0.32, p<0.0001). On the other hand, in the patients with a small coronary thrombus, the frequency of acute restenosis showed no difference in either group. The present study indicates that in patients with AMI, PTCA combined with pre-treatment of a low dose of urokinase is much more effective than PTCA alone, especially for those patients who have a large coronary thrombus.

Publication types

  • Comparative Study

MeSH terms

  • Angioplasty, Balloon, Coronary*
  • Cardiac Catheterization
  • Combined Modality Therapy
  • Coronary Artery Bypass
  • Coronary Disease / complications
  • Coronary Disease / drug therapy
  • Coronary Disease / therapy
  • Emergencies*
  • Fibrinolytic Agents / administration & dosage
  • Fibrinolytic Agents / adverse effects
  • Fibrinolytic Agents / therapeutic use*
  • Heart Rupture / etiology
  • Heart Rupture / mortality
  • Hemorrhage / chemically induced
  • Hemorrhage / epidemiology
  • Humans
  • Incidence
  • Myocardial Infarction / drug therapy
  • Myocardial Infarction / etiology
  • Myocardial Infarction / therapy*
  • Recurrence
  • Retrospective Studies
  • Shock, Cardiogenic / etiology
  • Shock, Cardiogenic / mortality
  • Thrombolytic Therapy* / adverse effects
  • Treatment Outcome
  • Urokinase-Type Plasminogen Activator / administration & dosage
  • Urokinase-Type Plasminogen Activator / adverse effects
  • Urokinase-Type Plasminogen Activator / therapeutic use*
  • Ventricular Fibrillation / etiology
  • Ventricular Fibrillation / mortality

Substances

  • Fibrinolytic Agents
  • Urokinase-Type Plasminogen Activator